In 1993, zaleplon (Sonata) was the first pyrazolopyrimidine investigated for clinical use as a hypnotic.
However, future research may reveal that all imidazopyridine, pyrazolopyrimidine, and cyclopyrrolone hypnotics can induce these parasomnias.
Interestingly, recently developed classes of hypnotic drugs - the imidazopyridines, pyrazolopyrimidines, and cyclopyrolones - can similarly cause sleep walking and other sleep behaviors (e.g., sleep-driving, sleep eating) as a side effect.
The '328 patent relates to the use of
pyrazolopyrimidine and 7-deazapurine nucleosides as replacements for the natural guanosine (G) nucleoside in nucleic acid probes.
Lader of the Institute of Psychiatry, London, reported the results of two open-label trials of zaleplon, a novel
pyrazolopyrimidine sleep medication that binds selectively and with low affinity to the brain benzodiazepine type 1 [gamma]-aminobutyric acid-receptor complex.
Lader of the Institute of Psychiatry London, reported the results of two open-label trials of zaleplon, a novel
pyrazolopyrimidine sleep medication that binds selectively and with low affinity to the brain benzodiazepine type 1 gammaaminobutyric acid-receptor complex.
Pyrazolopyrimidine substances have been synthesized since the 1970s.
Interestingly, recently developed classes of hypnotic drugs--the imidazopyridines, pyrazolopyrimidines, and cyclopyrolones--can similarly cause sleep walking and other sleep behaviors (e.g., sleep-driving, sleep eating) as a side effect.
(San Diego, CA) developer of advanced diagnostic products, announced that its subsidiary, Epoch Biosciences, was issued Patent 6,962,991, "Process for the synthesis of
pyrazolopyrimidines" by the United States Patent and Trademark Office.